Problem: In the world of pharmaceutical patents, it costs the patent originator money for R&D and patent application. After a patent is awarded, a generic manufacturer may challenge the patent using a "Paragraph 4" challenge, and doesn't have to pay any fee at all. There is, therefore, no cost for a generic manufacturer to challenge a legitimately awarded patent, and a big hidden cost to the originator (who has to plan on defending "Paragraph 4" challenges).
Solution: Require a fee for filing a "Paragraph 4" challenge. The fee for filing should match the fee-for-patent-application paid by the originator.
This reduces frivolous challenges to legitimate patents. Lowers "real" cost-per-patent to biotech entrepreneurs. Increases fairness in treatment of innovators and generic manufacturers.
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.